Topical Corticosteroids and Hospital Length of Stay in Children with Eczema Herpeticum

• Published in: Pediatric dermatology 2013-03, Vol.30 (2), p.215-221
• Main Authors: Aronson, Paul L., Shah, Samir S., Mohamad, Zeinab, Yan, Albert C.
• Format: Article
• Language: English
• Subjects: Administration, Topical; Adolescent; Adrenal Cortex Hormones - administration & dosage; Adrenal Cortex Hormones - therapeutic use; Child; Child, Preschool; Cohort Studies; Female; Hospitalization; Humans; Infant; Kaposi Varicelliform Eruption - drug therapy; Length of Stay - statistics & numerical data; Linear Models; Male; Retrospective Studies; Treatment Outcome
• ISSN: 0736-8046; 1525-1470
• DOI: 10.1111/j.1525-1470.2012.01859.x

:  There is concern that the use of topical corticosteroids in patients with eczema herpeticum may facilitate dissemination of herpes simplex virus and worsen disease. Our primary aim therefore was to determine whether topical corticosteroid use in children hospitalized with eczema herpeticum is associated with longer hospital length of stay (LOS). We performed a multicenter retrospective cohort study of 1,331 children ages 2 months to 17 years admitted with a diagnosis of eczema herpeticum between January 1, 2001, and March 31, 2010, to 42 tertiary care children’s hospitals in the Pediatric Health Information System database. Multivariable linear regression models determined the association between receipt of topical corticosteroid therapy on the first day of hospitalization and the main outcome measure: LOS. Receipt of topical corticosteroid therapy on day 1 of hospitalization was not associated with a longer LOS on unadjusted or multivariable analysis (p = 0.75). Receipt of topical calcineurin inhibitors during the hospitalization was also not associated with a longer LOS (p = 0.12). Receipt of systemic corticosteroids was associated with an 18% adjusted longer LOS (95% confidence interval 2%–36%; p = 0.03). Further study is needed to identify which children with eczema herpeticum may benefit from topical corticosteroids, but their use during active infection is not associated with poorer outcomes, although the use of systemic corticosteroids was associated with a longer LOS and should be avoided in patients with eczema herpeticum pending future prospective study.